文献速递传染病防控与疫情报告免疫规划

新冠mRNA疫苗在养老院居民中的有效性:Delta变异株前后对比

Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2021-08-27

本研究基于美国国家医疗安全网络(NHSN)2021年3月1日至8月1日的周报数据,评估辉瑞-BioNTech和Moderna mRNA疫苗在养老院居民中预防SARS-CoV-2感染的有效性。结果显示,调整后疫苗有效性在Delta变异株流行前为74.7%,中间期为67.5%,Delta流行期为53.1%,两种疫苗效果相似。研究表明mRNA疫苗可提供保护,但Delta变异株流行后有效性下降。

要点

  • 养老院居民全程接种mRNA疫苗对SARS-CoV-2感染的有效性在Delta流行前为74.7%,Delta流行期为53.1%。
  • 辉瑞-BioNTech和Moderna疫苗的有效性估计相似。
  • 尽管接种疫苗,养老院居民仍可能面临感染风险,需综合防控措施。

核心结论

  • mRNA疫苗在养老院居民中可预防SARS-CoV-2感染,但Delta变异株成为主要流行株后疫苗有效性下降。

研究设计与样本

  • 基于美国国家医疗安全网络(NHSN)每周报告的回顾性分析,纳入2021年3月1日至8月1日期间养老院数据。
  • Delta前时期(2021年3月1日至5月9日)使用3,862家机构的17,407份周报。
  • 中间期(2021年5月10日至6月20日)使用11,581家机构的33,160份周报。
  • Delta期(2021年6月21日至8月1日)使用14,917家机构的85,593份周报。

主要发现

  • Delta前时期调整后疫苗有效性为74.7%(95%CI=70.0%-78.8%)。
  • 中间期调整后疫苗有效性为67.5%(95%CI=60.1%-73.5%)。
  • Delta期调整后疫苗有效性为53.1%(95%CI=49.1%-56.7%)。
  • 辉瑞-BioNTech和Moderna疫苗的有效性估计相似。

临床怎么用

  • 养老院居民即使接种疫苗仍可能感染SARS-CoV-2,需继续采取感染控制、检测和工作人员、居民及访客接种疫苗等多重预防策略。
  • 可考虑为养老院和长期护理机构居民接种额外剂次新冠疫苗以优化保护性免疫应答。

局限性

  • 分析评估的是对任何感染的有效性,无法区分无症状和症状性感染。
  • 需要进一步评估随时间推移对重症疾病的保护效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nursing home and long-term care facility residents live in congregate settings and are often elderly and frail, putting them at high risk for infection with SARS-CoV-2, the virus that causes COVID-19, and severe COVID-19-associated outcomes; therefore, this population was prioritized for early vaccination in the United States (1). Following rapid distribution and administration of the mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) under an Emergency Use Authorization by the Food and Drug Administration (2), observational studies among nursing home residents demonstrated vaccine effectiveness (VE) ranging from 53% to 92% against SARS-CoV-2 infection (3-6). However, concerns about the potential for waning vaccine-induced immunity and the recent emergence of the highly transmissible SARS-CoV-2 B.1.617.2 (Delta) variant† highlight the need to continue to monitor VE (7). Weekly data reported by the Centers for Medicaid & Medicare (CMS)-certified skilled nursing facilities or nursing homes to CDC's National Healthcare Safety Network (NHSN)§ were analyzed to evaluate effectiveness of full vaccination (2 doses received ≥14 days earlier) with any of the two currently authorized mRNA COVID-19 vaccines during the period soon after vaccine introduction and before the Delta variant was circulating (pre-Delta [March 1-May 9, 2021]), and when the Delta variant predominated¶ (Delta [June 21-August 1, 2021]). Using 17,407 weekly reports from 3,862 facilities from the pre-Delta period, adjusted effectiveness against infection for any mRNA vaccine was 74.7% (95% confidence interval [CI] = 70.0%-78.8%). Analysis using 33,160 weekly reports from 11,581 facilities during an intermediate period (May 10-June 20) found that the adjusted effectiveness was 67.5% (95% CI = 60.1%-73.5%). Analysis using 85,593 weekly reports from 14,917 facilities during the Delta period found that the adjusted effectiveness was 53.1% (95% CI = 49.1%-56.7%). Effectiveness estimates were similar for Pfizer-BioNTech and Moderna vaccines. These findings indicate that mRNA vaccines provide protection against SARS-CoV-2 infection among nursing home residents; however, VE was lower after the Delta variant became the predominant circulating strain in the United States. This analysis assessed VE against any infection, without being able to distinguish between asymptomatic and symptomatic presentations. Additional evaluations are needed to understand protection against severe disease in nursing home residents over time. Because nursing home residents might remain at some risk for SARS-CoV-2 infection despite vaccination, multiple COVID-19 prevention strategies, including infection control, testing, and vaccination of nursing home staff members, residents, and visitors, are critical. An additional dose of COVID-19 vaccine might be considered for nursing home and long-term care facility residents to optimize a protective immune response.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34437519. doi:10.15585/mmwr.mm7034e3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。